R

Revolution Medicines

Clinical-stage oncology company developing RAS inhibitors

Director – Health Economics and Outcomes Research & RWE

Biology & BiotechConfirmed live in the last 24 hours
Full-timeBasel, SwitzerlandNo salary listed

About the Job

Requirements

  • Deep expertise in health economics, outcomes research, patient-reported outcomes, or related fields in the biotechnology or pharmaceutical industry.
  • Experience in oncology health economics and outcomes research and real-world evidence development.
  • At least 10 years of relevant experience and an advanced degree in a relevant field, such as an MSc, DrPH, or PharmD.
  • A track record of high-impact publications in health economics and outcomes research and real-world evidence topics.
  • Knowledge and experience of the European health technology assessment and pricing and reimbursement landscape.
  • Ability to establish relationships with real-world evidence and therapeutic-area experts.

Responsibilities

  • Lead, own, and evolve the European health economics and outcomes research and real-world evidence strategy for assigned assets, disease areas, and evidence-generation workstreams across the product lifecycle.
  • Set evidence priorities and success measures to support medical strategy, value demonstration, pricing and reimbursement, and local health technology assessment submissions.
  • Assess, prioritize, and articulate European evidence needs; ensure plans address evidence gaps and regional and local requirements, with clear deliverables, accountabilities, timelines, and decision points.
  • Direct and be accountable for the design, execution, scientific quality, and delivery of health economic models, including cost-effectiveness and budget-impact models; real-world evidence; burden-of-disease assessments; patient-centered outcomes research; and other evidence packages supporting regulatory filings, joint clinical assessments and health technology assessment submissions, reimbursement decisions, and payer engagement.
  • Partner with Medical Affairs, Market Access, Commercial, Regulatory, Clinical Development, Global Health Economics and Outcomes Research, and local affiliates to integrate payer and evidence requirements into development, launch, and lifecycle plans; resolve priorities and trade-offs; and drive timely execution.
  • Represent Revolution Medicines in European health economics and outcomes research and real-world evidence scientific, payer, and health technology assessment forums.
  • Drive strategic engagement with key opinion leaders, academic collaborators, health technology assessment bodies, payers, data partners, and other external stakeholders to inform evidence plans and strengthen value demonstration.
  • Select, direct, and hold external consultants, research partners, and vendors accountable for scope, methodology, scientific quality, budget, timelines, risk management, and final outputs; ensure deliverables are fit for purpose and support agreed business and evidence objectives.
  • Develop and deliver scientifically robust health economics and outcomes research and real-world evidence narratives, evidence summaries, value messages, and dissemination plans for senior leadership and external audiences.
  • Translate complex findings into actionable recommendations and ensure consistency across European and global stakeholders.

Desired Qualifications

  • An advanced medical or scientific doctoral-level degree, such as a PhD or MD.
  • Personnel management experience, including leading health economics and outcomes research scientists.

About the Company

Revolution Medicines

Clinical-stage oncology company developing RAS inhibitors

Revolution Medicines develops precision oncology drugs focused on cancers driven by RAS mutations. Its RAS(ON) inhibitors are small molecules that bind the active form of RAS to block cancer signaling, with candidates like Daraxonrasib (RMC-6236), Elironrasib (RMC-6291), and Zoldonrasib (RMC-9805) advancing in global Phase 3 trials. The company funds its research through collaborations, royalties, and upfront funding, and has not yet marketed a product. Its goal is to bring effective RAS-targeted therapies to patients and advance multiple candidates through late-stage trials toward approval, supported by strong cash reserves.

Company size
1,001-5,000
Company stage
IPO
Headquarters
Redwood City, CA
Founded
2014

Recently Posted Jobs

Explore more opportunities at Revolution Medicines

See more jobs